- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00644605
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
New South Wales
-
Darlinghurst, New South Wales, Australien, 2010
- Pfizer Investigational Site
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Pfizer Investigational Site
-
-
-
-
-
Bruxelles, Belgien, 1070
- Pfizer Investigational Site
-
Leuven, Belgien, 3000
- Pfizer Investigational Site
-
-
-
-
SP
-
Sao Paulo, SP, Brasilien, 05403-900
- Pfizer Investigational Site
-
-
-
-
-
Kobenhavn, Danmark, 2100
- Pfizer Investigational Site
-
-
-
-
-
Clamart, Frankrike, 92141
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, Förenta staterna, 35294
- Pfizer Investigational Site
-
Birmingham, Alabama, Förenta staterna, 35294-0006
- Pfizer Investigational Site
-
-
California
-
La Jolla, California, Förenta staterna, 92037
- Pfizer Investigational Site
-
La Jolla, California, Förenta staterna, 92093
- Pfizer Investigational Site
-
Los Angeles, California, Förenta staterna, 90095
- Pfizer Investigational Site
-
Los Angeles, California, Förenta staterna, 90033
- Pfizer Investigational Site
-
Los Angeles, California, Förenta staterna, 90024
- Pfizer Investigational Site
-
San Diego, California, Förenta staterna, 92037
- Pfizer Investigational Site
-
Torrance, California, Förenta staterna, 90502
- Pfizer Investigational Site
-
Torrance, California, Förenta staterna, 90509
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80010
- Pfizer Investigational Site
-
Denver, Colorado, Förenta staterna, 80262
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Pfizer Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, Förenta staterna, 71103
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02111
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53215
- Pfizer Investigational Site
-
-
-
-
-
Shatin N T, Hong Kong
- Pfizer Investigational Site
-
-
-
-
-
Petach Tikva, Israel, 49100
- Pfizer Investigational Site
-
Tel Hashomer, Israel, 52621
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italien, 40138
- Pfizer Investigational Site
-
Pisa, Italien, 56124
- Pfizer Investigational Site
-
Pisa, Italien, 56126
- Pfizer Investigational Site
-
-
-
-
-
Suwon, Korea, Republiken av, 442-721
- Pfizer Investigational Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Pfizer Investigational Site
-
-
-
-
-
Tlalpan, Mexiko
- Pfizer Investigational Site
-
-
-
-
-
Amsterdam, Nederländerna, 1081 HV
- Pfizer Investigational Site
-
-
-
-
-
Oslo, Norge, NO-0027
- Pfizer Investigational Site
-
-
-
-
-
Katowice, Polen, 40-057
- Pfizer Investigational Site
-
Warszawa, Polen, 01-138
- Pfizer Investigational Site
-
Warszawa, Polen, 03-709
- Pfizer Investigational Site
-
Zabrze, Polen, 41-800
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapore, 168752
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Pfizer Investigational Site
-
Barcelona, Spanien, 08036
- Pfizer Investigational Site
-
Madrid, Spanien, 28041
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, Storbritannien, G11 6NT
- Pfizer Investigational Site
-
HIGH Heaton, Newcastle-upon-tyne, Storbritannien, NE7 7DW
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Papworth Everard, Cambridgeshire, Storbritannien, CB3 8RE
- Pfizer Investigational Site
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Storbritannien, S10 2JF
- Pfizer Investigational Site
-
-
-
-
-
Goteborg, Sverige, 413 45
- Pfizer Investigational Site
-
Molndal, Sverige, 431 80
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, Sydafrika, 7700
- Pfizer Investigational Site
-
Johannesburg, Sydafrika, 2193
- Pfizer Investigational Site
-
Parow, Sydafrika
- Pfizer Investigational Site
-
-
-
-
-
Prague 4, Tjeckien, 140 00
- Pfizer Investigational Site
-
Prague 4, Tjeckien, 140 21
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13353
- Pfizer Investigational Site
-
Giessen, Tyskland, 35385
- Pfizer Investigational Site
-
Giessen, Tyskland, 35392
- Pfizer Investigational Site
-
Hannover, Tyskland, 30625
- Pfizer Investigational Site
-
Leipzig, Tyskland, 04103
- Pfizer Investigational Site
-
-
-
-
Pest
-
Budapest, Pest, Ungern, 1529
- Pfizer Investigational Site
-
-
Zala
-
Zalaegerszeg, Zala, Ungern, 8900
- Pfizer Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Included patients had primary pulmonary arterial hypertension, pulmonary hypertension secondary to connective tissue disease, or pulmonary hypertension with surgical repair at least 5 years previously; a mean pulmonary artery pressure greater than or equal to 25 mmHg and a pulmonary artery wedge pressure of less than or equal to 15 mmHg at rest, via right heart catheterisation within 21 days prior to randomisation; and a baseline 6-Minute Walk test distance of 100 m to 450 m.
Exclusion Criteria:
Subjects with congenital heart disease, pulmonary hypertension due to thromboembolism, HIV, chronic obstructive airway disease, congestive heart failure or schistosomiasis; subjects with significant (ie > 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation; and acutely decompensated heart failure within the previous 30 days; subjects with pulmonary hypertension secondary to any other etiology other than those specified in the inclusion criteria.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Arm 2
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Aktiv komparator: Arm 1
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Placebo-jämförare: Arm 4
|
placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Aktiv komparator: Arm 3
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test).
Tidsram: Week 12
|
Week 12
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Change from baseline in mean pulmonary arterial pressure
Tidsram: Week 12
|
Week 12
|
Time from randomisation to the first occurrence of clinical worsening (death or lung transplantation or hospitalisation due to pulmonary hypertension or initiation of prostacyclin therapy or initiation of bosentan therapy)
Tidsram: Week 0 to 12
|
Week 0 to 12
|
Change from baseline in the BORG dyspnoea score
Tidsram: Week 12
|
Week 12
|
Change from baseline in pulmonary hypertension criteria for functional capacity and therapeutic class
Tidsram: Week 12
|
Week 12
|
Change from baseline in the 8 dimensions of SF-36 (Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, Mental health and Reported health transition)
Tidsram: Week 4 and Week 12
|
Week 4 and Week 12
|
Change from baseline at Weeks 4 and 12 in the 5 dimensions of ED5Q (Mobility, Self care, Usual Activities, Pain/Discomfort and Anxiety/Depression)
Tidsram: Week 4 and Week 12
|
Week 4 and Week 12
|
Patient overall preference assessment
Tidsram: Week 12
|
Week 12
|
Change in Chronic Use of Background Therapy for Pulmonary Arterial Hypertension
Tidsram: throughout the study
|
throughout the study
|
Change from baseline in hemodynamic parameters
Tidsram: Week 12
|
Week 12
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- A1481140
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hypertoni, lung
-
Biodesix, Inc.Aktiv, inte rekryterandeNSCLC | Nodule Solitary PulmonaryFörenta staterna
-
Biodesix, Inc.RekryteringIcke-småcelligt karcinom | Nodule Solitary PulmonaryFörenta staterna, Kanada
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Avslutad
-
NovartisAvslutad
-
Beijing Aerospace General HospitalAvslutadSutur | Videoassisterad torakoskopisk kirurgi | Nodule, Solitary PulmonaryKina
-
NovartisAvslutadMETABOLISKT SYNDROM | HYPERTENSION | PRE-HYPERTENSIONFörenta staterna
-
Centre Chirurgical Marie LannelongueOkändKronisk trombo-embolisk pulmonell hypertension och pulmonell arteriell hypertensionFrankrike
-
University of California, San FranciscoNorthern California Institute of Research and Education; Guardant Health...RekryteringIcke-småcellig lungcancer | Nodule Solitary PulmonaryFörenta staterna
-
NovartisAvslutadHYPERTENSION | HYPERKOLESTEROLEMIFörenta staterna
Kliniska prövningar på sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRekrytering
-
Rambam Health Care CampusOkänd
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerAvslutad
-
Pfizer's Upjohn has merged with Mylan to form Viatris...AvslutadFarmakokinetiken för sildenafil oralt sönderfallande tablettformulering kontra Viagra® oral tablett.Erektil dysfunktionSingapore
-
The Cleveland ClinicAvslutadPulmonell hypertoni | Diffus parenkymal lungsjukdomFörenta staterna
-
iX Biopharma Ltd.Linear Clinical ResearchAvslutadErektil dysfunktionAustralien
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenAvslutadBeckers muskeldystrofiDanmark
-
N4 Pharma UK Ltd.BDD Pharma LtdAvslutadErektil dysfunktionStorbritannien
-
University Hospital, GrenobleAvslutad
-
University Hospital, MontpellierIndragenPulmonell hypertoni | Enkelkammar | Univentrikulärt hjärta